

General Billing Information for Clinicians

Adaptive Biotechnologies understands that each patient's situation is unique. We are committed to providing guidance and support during each step of the insurance and billing process. Adaptive believes every qualified patient who could benefit from the clinical insights provided by next-generation measurable residual disease (MRD) testing should have access to the clonoSEQ® Assay, regardless of their insurance or financial status. Adaptive works with all types of insurance plans and offers a Patient Support Program for eligible patients.

GENERAL INFORMATION

For Medicare Patients

Medicare covers clonoSEQ testing when pre-determined criteria are met under a National Coverage Determination (NCD), Local Coverage Determination (LCD), or Local Coverage Article (LCA). The Centers for Medicare & Medicaid Services (CMS) requires non-covered patients to complete an Advance Beneficiary Notice (ABN) prior to receiving testing services. You can access the full coverage policy details for clonoSEQ via the [CMS website](#). Completed ABN forms can be uploaded to the Adaptive Diagnostics Portal, included with a sample submitted for testing, or faxed to our Clinical Services team at 1-866-623-4408. For more information or to download an ABN form, visit www.clonoSEQ.com/ordering or www.cms.gov/Medicare/Medicare-General-Information/BNI/ABN.html.

Following testing, in most situations, Medicare will be billed directly by Adaptive Biotechnologies.

For Commercially Insured Patients

We work with all insurance plans; depending on the type of insurance your patient has, coverage for clonoSEQ testing may differ. If the insurance company sends payment directly to your patient, please have them forward the check to Adaptive as soon as possible. In the event a patient's insurance company denies coverage for clonoSEQ testing, Adaptive will work on the patient's behalf to pursue appropriate appeals and obtain coverage. Additional information to support the appeal process may be needed from your office (ex. letter of medical necessary, medical records) and/or the patient (ex. patient consent to appeal).

For Uninsured Patients

Adaptive will bill patients directly for testing services. Please inform your patients that they can apply for assistance or inquire about a payment plan through Adaptive Assist™, our Patient Support Program.


About the Adaptive Assist Patient Support Program

Our Patient Support Program is designed to help facilitate access to clonoSEQ testing services. It is a comprehensive support program providing services to assist the patient for the duration of the billing process. These services include:

- Aiding patients to understand the billing process and managing all aspects of billing their insurance
 - Out-of-pocket estimates are available **prior to submission¹ of a clonoSEQ order** by contacting our hotline at 1-855-236-9230. To obtain estimates multiple patients at one time please send the patients' insurance information via fax to 206-299-0488
- Assisting in obtaining prior authorizations for all incoming clonoSEQ clinical orders
- Appealing claims (with patient consent) to obtain coverage at the highest possible benefit level for the patient
- Assisting eligible patients to manage any out-of-pocket costs once clonoSEQ is covered

More information on the Patient Support Program is available at www.Adaptive-Assist.com. Our Patient Support Team can be reached at 1-855-236-9230 for information on Adaptive Assist, billing questions, and to access Adaptive Assist services.

Our Billing Process



Questions about our billing process? Contact our Patient Support Team at 1-855-236-9230. Representatives are available Monday to Thursday 9AM to 7PM and Friday 9AM to 5PM ET.

1. Estimate of Potential Out-of-Pocket Costs for Testing: Adaptive offers a clonoSEQ benefits investigation service upon request. Either the patient or your staff can call our Patient Support Hotline at 855-236-9230 prior to the ordering of a test to ask for a benefits investigation. The caller will need to have the patient's insurance information on hand. Requests for benefits investigation should be submitted prior to sending a sample to Adaptive for testing; we cannot cancel tests for samples that have already been received and accepted by our lab.

- Please remember that any amount quoted during this process is an estimate based on plan benefits and unmet deductible, co-insurance, and/or co-pay amounts at the time of the benefits investigation. This amount is subject to change based on other claims that are being processed for the patient.

clonoSEQ is available as an FDA-cleared *in vitro* diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.